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| INTRODUC TI ON
Combined hormonal contraceptives (CHC) are the most common birth control method used worldwide and are increasingly used by adolescent women.
1-3 CHC are proven effective for contraception and generally safe. 4 Because menopausal oestrogen treatment is positive for bone health, it has been assumed that CHC use would also be boneprotective. The association of CHC use with areal bone mineral density (BMD) change has only been documented since the mid-1990s.
5
Adolescence is a key time in women's life cycle for bone accrual, for decreasing later life osteoporosis and lifetime fragility fracture risk. 6, 7 Premenopausal BMD values are related to prevalent fractures in a cross-sectional evaluation of the adult population-based Canadawide Canadian Multicentre Osteoporosis Study (CaMos). 8 Peak BMD at both the femoral neck and the total hip is gained in women between ages 16 and 19 years and lumbar spine peak BMD is achieved between ages 33 and 40 in prospective population-based data from the Youth and Adult CaMos Cohorts. 9 Those who achieve a lower peak BMD are widely believed to be at increased risk of later life fractures, 6, 7 although prospective BMD and incident fragility fracture data are scarce.
Genetics accounts for more than 50% of peak bone mass; as well, a family history of fragility fracture has recently been shown to increase premenopausal BMD loss. 10 However, factors such as adequate calcium and other nutrition, 11 menstrual cycle/ovulatory disturbances 12 and physical activity 13 also influence peak BMD acquisition.
Increasingly, adolescent women are prescribed CHC for noncontraceptive indications such as cramps, acne and irregular cycles 2 ;
there is thus a need to understand the potential relationship of CHC use with adolescent women's peak BMD acquisition. CHC use may be a concern in adolescence because, to accrue peak BMD, active bone growth through modelling is necessary, and this requires bone formation. CHC has long been known to suppress bone remodelling.
14 Since oestrogen decreases bone turnover and suppresses bone resorption, it is positive for the adult skeleton that is generally in a state of bone loss. The dynamic bone state in adolescence is different. Supraphysiological ethinyl oestradiol (EE) doses are needed for effective contraception; therefore, use of CHC in adolescence may suppress bone growth as it suppresses bone resorption since the two processes are coupled. 2, 3 Suppression of bone biomarker levels has been documented even with CHC EE doses as low as 20 µg which is considered "low dose" compared with earlier CHC products. 5, 15, 16 We carried out a meta-analysis of published data reporting prospective BMD changes in healthy adolescent women with first use of CHC and in nonusing controls. Our hypothesis was that CHC use would impair adolescent BMD accrual.
| MATERIAL S AND ME THODS
The Cochrane handbook for systematic reviews and MOOSE checklist criteria were applied in designing, conducting and reporting this systemic review and meta-analysis. A standardized (unpublished) protocol defined types of studies and outcomes related to our 
| Search strategy
Our literature search strategy is summarized in Table S1 . 
| Inclusion/exclusion criteria
We sought peer-reviewed published papers on prospective obser- ods of delivery is to achieve a "supraphysiological" dose equivalent oestrogen value with a near-"physiological" progestin concentration.
However, no full study used these other CHC delivery methods and there was only one person in the large Brajic study who reported use of the vaginal ring.
We excluded cross-sectional designs, progestin-only contraceptive use, depot-medroxyprogesterone or progestin-releasing IUD use, or continuous or long-cycle CHC use. We excluded studies that did not measure BMD using dual-energy X-ray absorptiometry (DXA). We also excluded studies of adolescent women with known bone-affecting conditions such as amenorrhoea, anorexia nervosa or osteogenesis imperfecta. All languages were included; all retrieved, eligible studies, however, were in English. Finally, we excluded studies that did not measure and report BMD at standard intervals of baseline, 12 months and/or 24 months.
| Data extraction
Primary searches of databases and screening of abstracts were iteratively performed independently by two authors (TSB and AG) between 2014 and 2017. After eliminating noneligible studies, data from full texts were extracted using a customized table. JCP reviewed and compared the extracted with the primary data. The final eligible studies were decided by consensus (TSB, AG and JCP).
When the same study population was reported in multiple publications, only the report with the most statistical power was included.
Risk of bias was assessed by the Newcastle-Ottawa Quality Assessment Scale (http://www.ohri.ca/programs/clinical_epidemi-ology/oxford.asp) for Cohort Studies based on selection of participant groups, their comparability and outcome ascertainment in each group. 17 Final evaluation was performed independently by JCP and AG who, if there were disagreements, came to agreement by consensus (Table S2) .
Two manuscripts were published and added after primary searches with the last search being in January 2018. In studies that compared CHC agents having different EE doses with non-using controls, following Cochrane guidelines, different dose formulations were statistically combined into a single group. 18 We included the published data from the population-based, country-wide CaMos Youth Cohort. 3 The following data were extracted for each study: study design, participant age, sample size, follow-up length, CHC preparation(s), BMD at the baseline and at 12-and 24-month follow-up periods (as relevant) and, if available, any reported adjustment for confounding variables such as body mass index (BMI), calcium intakes, racial origin and cigarette smoking history.
| Statistical analysis
The standard deviation (SD) of mean absolute BMD change was often not reported. If not available from authors, we used values from the CaMos Youth Cohort Cohort adolescent data. 3 For the 24-month analysis, we used the SD of absolute lumbar spine BMD change in CHC-using and nonusing women from CaMos after 24 months to impute the SD for other 24-month duration studies. We included data from lumbar spine levels L1-4; actual segmental levels, however, were rarely noted in these publications. Figure 3 ). This was a highly statistically significant result with P < 0.0006. There was also an important degree of heterogeneity in this comparison (I 2 = 85%).
To analyse whether the negative effects of the CHC on BMD change were continuing to increase at 24 months in the same proportion as the 12-month results for the four studies which had data for both 12 and 24 months, we performed a different meta-analysis.
We found that in four studies with both 12-and 24-month data, the Cromer data, 15 however, reduced the heterogeneity; I 2 changed from 85% to 74%. There was no study that had no overlap with the effect size in the 24-month analysis. In 12-month analysis, however, Biason et al could be considered an outlier, but we could not find any characteristics that made it different from other studies in terms of sample size, inclusion criteria, CHC dosing or other demographic features. Removing it from the meta-analysis also made no difference to the outcome.
TA B L E 1 Descriptive characteristics of studies included in the primary pooled analyses of prospective studies of adolescent women and areal bone mineral density (BMD) change by use of combined hormonal contraceptives (CHC) or not The two CHC arms in these studies were randomized and blinded, but the controls were open-label and nonrandomized. This randomized controlled trial compared the two CHC groups but had a nonrandomized control group thus it became a prospective observational study F I G U R E 2 This random-effects forest plot assessed the 12-mo weighted mean difference in mean absolute change from baseline in g/ cm for spinal areal bone mineral density (BMD) in adolescent-combined hormonal contraceptives (CHC) users and nonusers/controls [Colour figure can be viewed at wileyonlinelibrary.com]
| D ISCUSS I ON
This first meta-analysis of prospective changes in spinal bone mineral density in healthy adolescents, comparing those first using oestrogen-progestin CHC agents with similar CHC nonusers, showed significantly less lumbar spine 24-month BMD accrual in those on CHC. These results are of public health relevance because today a higher percentage of women are starting CHC in adolescence rather than in early adulthood as was true in the past. There are several strengths of this study including that it is the first quantitative synthesis of studies of change in spinal BMD in adolescent women using and not using CHC. In addition, we reported absolute change in g/cm 2 to avoid the biasing influence of the baseline value on percentage change. 27 Finally, it is a strength that the authors of publications with wider age ranges of participants have provided their adolescent-only data. 16, 19, 20 A limitation is that there are no randomized, placebo-controlled trials of BMD change on CHC vs CHC nonusing adolescent women.
We were able to find sufficient quantitative data from observational prospective studies and from two randomized trials of different CHC
agents compared with open-label controls. We were unable to obtain sufficient data for quantitative analysis of all the publications that have relevant primary research data. Few studies have reported whole body BMD change, a usual adolescent clinical BMD measurement site. We also could not uniformly adjust these BMD change data for BMI, race and cigarette smoking, important variables in adolescent bone acquisition. Although the 24-month weighted mean spinal BMD change difference between CHC users and nonusers was small (−0.02 g/cm 2 per 2 years), this difference is 60% of a SD of the 2-year BMD change in CaMos population-based CHC nonusing controls. 3 In randomized placebo-controlled therapy trials in menopausal women, as small a difference in BMD change as 1% per year was associated with an 8% decrease in subsequent fracture risk.
28
Perhaps the major limitation of this study is high heterogeneity of the included studies. Several measures are recommended for dealing with high heterogeneity in meta-analysis: carrying out a metaregression and/or conducting a subgroup analysis to name a few;
however, the small number of eligible studies in the analysis did not allow any further adjustment in our case. However, our 24-month results were robust to sensitivity analyses especially since a randomeffects model does not assume homogeneity of effects. We had insufficient power to assess oestrogen doses or to differentiate the potential BMD effects of the various progestins that are commonly part of CHC. We were also unable, due to few eligible publications, to accurately evaluate publication bias.
There has been ongoing and legitimate skepticism that CHCrelated negative cross-sectional BMD data even, if it is in a population-based cohort, 25 and adolescent BMD loss data as in this meta-analysis, are simply surrogate markers that may or may not reflect the principal medical outcome of fractures. However, the literature includes three large prospective cohort studies of CHCusing women showing incident fracture risks of 7-30% higher than in controls who never used CHC. [29] [30] [31] In summary, significantly less spinal bone mineral density accrual occurs in adolescent women who were first taking combined hormonal contraceptives compared with those not using them. This suggests that CHC, even though now including much lower oestrogen doses than in the past, still has sufficiently high doses to decrease bone turnover and thus to likely suppress the bone formation necessary for optimal adolescent bone growth to peak BMD. Since CHC use is now commonly started during adolescence and is recommended for treatment of mild symptomatic, non-contraceptive reasons such as acne and cramps, 2 there may be a negative public health impact from this current practice. These analysed data can only show associations; therefore, randomized placebo-controlled trial data directly comparing CHC and CHC nonusers' BMD changes are needed. 
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